Press Esc to close

Welcome to Money Morning - Only the News You Can Profit From.

Close

While Washington Stews, You Can Cash In on the Biggest "Tax-Inversion" Deal in History

Back in June 2012, we recommended that you pick up shares of Big Pharma player Abbott Laboratories Inc. (NYSE: ABT). The reason: Abbott was planning to split in two at the end of the year, meaning folks who took our advice would end up with stakes in two companies for the price of one.

There was more than bargain-basement thinking at work here.

You see, these corporate breakups – known as spin-offs – have a habit of turning into market-beating profit plays. And the newly minted spin-off firms often end up as takeover fodder – also at big profits.

Abbott followed part of that blueprint.

  • Drug Stocks to Buy: New Statin Guidelines Are a Shot in the Arm for These Generics O They account for 264 million prescriptions annually in the U.S. alone, and $35 billion in annual global sales. Now doctors say these drugs could help treat an entirely different ailment, which affects hundreds of millions of people worldwide. That means sales are about to skyrocket. And just two drug companies will reap the lion's share of the profits...
  • Drug Stocks a Good Buy Now as Pharma M&A Hits $50 Billion Doctor with medical health record Drug maker Shire has announced it will buy ViroPharma for $4.2 billion. This comes on the heels of Amgen's $10.4 billion offer for Onyx Pharmaceuticals in August and Perrigo's acquisition of Elan Corp. in July for $8.6 billion. Those are just a few of the dozens of pharma deals this year that have enriched shareholders. The good news? This is only the beginning. You, too, can profit from this "feeding frenzy"...
  • 4 Drug Stocks to Buy Now to Capitalize on Emerging Market Growth Drug bottles Overall, this sector has healthy global sales of $959 billion and is expected to grow those sales at a rate of 4.5% a year. But in emerging markets, sales in this sector will grow at three times that rate. And on top of that, another development will make these markets even more lucrative. We've identified the handful of companies best-positioned to take advantage of this...
  • Is This Drug the Key to an Alzheimer's Cure? Among the top 10 causes of death by disease, Alzheimer's is the only one that cannot be cured, treated, or slowed down. But that may be about to change - and a vaccine could soon be at hand. Read More...